Bullfrog AI (BFRG) vs Karyopharm Therapeutics (KPTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bullfrog AI (BFRG) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 55.6% versus a loss of 89.8%. Karyopharm Therapeutics is the larger company by market cap ($13.7 million vs $12.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRG | KPTI |
|---|---|---|
| Share price | $0.646 | $0.605 |
| Market cap | $11.98M | $13.72M |
| 1-day change | -6.70% | +0.83% |
| YTD return | -21.59% | -91.85% |
| 1-year return | -55.62% | -89.83% |
| 5-year return | — | -99.28% |
| EPS (TTM) | $-0.46 | $-14.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.96 | $10.99 |
| 52-week low | $0.425 | $0.5652 |
| Distance from 52-week high | -67.04% | -94.49% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +1098.35% |
| Average volume | 5.34M | 1.71M |
| Shares outstanding | 18.54M | 22.68M |
| Employees | 9 | 228 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRG has outperformed KPTI by 34.2 percentage points over the past year.
About Bullfrog AI
BFRG stock →Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Health Care · Biotechnology: Pharmaceutical Preparations · 228 employees
BFRG vs KPTI FAQ
Which is bigger, Bullfrog AI or Karyopharm Therapeutics?
Karyopharm Therapeutics (KPTI) is larger, with a market capitalization of $13.72M compared with $11.98M for Bullfrog AI (BFRG).
Which stock has performed better over the past year, BFRG or KPTI?
BFRG returned -55.62% over the past 12 months, compared with -89.83% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Bullfrog AI and Karyopharm Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.